Literature DB >> 25878338

Rapid Detection of Emerging Pathogens and Loss of Microbial Diversity Associated with Severe Lung Disease in Cystic Fibrosis.

William G Flight1, Ann Smith2, Christopher Paisey2, Julian R Marchesi3, Matthew J Bull2, Phillip J Norville2, Ken J Mutton4, A Kevin Webb5, Rowland J Bright-Thomas5, Andrew M Jones5, Eshwar Mahenthiralingam6.   

Abstract

Respiratory infection in cystic fibrosis (CF) is polymicrobial, but standard sputum microbiology does not account for the lung microbiome or detect changes in microbial diversity associated with disease. As a clinically applicable CF microbiome surveillance scheme, total sputum nucleic acids isolated by a standard high-throughput robotic method for accredited viral diagnosis were profiled for bacterial diversity using ribosomal intergenic spacer analysis (RISA) PCR. Conventional culture and RISA were performed on 200 paired sputum samples from 93 CF adults; pyrosequencing of the 16S rRNA gene was applied to 59 patients to systematically determine bacterial diversity. Compared to the microbiology data, RISA profiles clustered into two groups: the emerging nonfermenting Gram-negative organisms (eNFGN) and Pseudomonas groups. Patients who were culture positive for Burkholderia, Achromobacter, Stenotrophomonas, and Ralstonia clustered within the eNFGN group. Pseudomonas group RISA profiles were associated with Pseudomonas aeruginosa culture-positive patients. Sequence analysis confirmed the abundance of eNFGN genera and Pseudomonas within these respective groups. Low bacterial diversity was associated with severe lung disease (P < 0.001) and the presence of Burkholderia (P < 0.001). An absence of Streptococcus (P < 0.05) occurred in individuals with lung function in the lowest quartile. In summary, nucleic acids isolated from CF sputum can serve as a single template for both molecular virology and bacteriology, with a RISA PCR rapidly detecting the presence of dominant eNFGN pathogens or P. aeruginosa missed by culture (11% of cases). We provide guidance for how this straightforward CF microbiota profiling scheme may be adopted by clinical laboratories.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25878338      PMCID: PMC4473198          DOI: 10.1128/JCM.00432-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis.

Authors:  William G Flight; Rowland J Bright-Thomas; Peter Tilston; Kenneth J Mutton; Malcolm Guiver; Julie Morris; A Kevin Webb; Andrew M Jones
Journal:  Thorax       Date:  2013-10-14       Impact factor: 9.139

2.  STAMP: statistical analysis of taxonomic and functional profiles.

Authors:  Donovan H Parks; Gene W Tyson; Philip Hugenholtz; Robert G Beiko
Journal:  Bioinformatics       Date:  2014-07-23       Impact factor: 6.937

3.  Enacyloxins are products of an unusual hybrid modular polyketide synthase encoded by a cryptic Burkholderia ambifaria Genomic Island.

Authors:  Eshwar Mahenthiralingam; Lijiang Song; Andrea Sass; Judith White; Ceri Wilmot; Angela Marchbank; Othman Boaisha; James Paine; David Knight; Gregory L Challis
Journal:  Chem Biol       Date:  2011-05-27

4.  Culture-independent analysis of bacterial fuel contamination provides insight into the level of concordance with the standard industry practice of aerobic cultivation.

Authors:  Judith White; Jack Gilbert; Graham Hill; Edward Hill; Susan M Huse; Andrew J Weightman; Eshwar Mahenthiralingam
Journal:  Appl Environ Microbiol       Date:  2011-05-20       Impact factor: 4.792

5.  Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota.

Authors:  Amanda F Goddard; Benjamin J Staudinger; Scot E Dowd; Amruta Joshi-Datar; Randall D Wolcott; Moira L Aitken; Corinne L Fligner; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-07       Impact factor: 11.205

6.  Decade-long bacterial community dynamics in cystic fibrosis airways.

Authors:  Jiangchao Zhao; Patrick D Schloss; Linda M Kalikin; Lisa A Carmody; Bridget K Foster; Joseph F Petrosino; James D Cavalcoli; Donald R VanDevanter; Susan Murray; Jun Z Li; Vincent B Young; John J LiPuma
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

7.  Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis.

Authors:  Paul C Blainey; Carlos E Milla; David N Cornfield; Stephen R Quake
Journal:  Sci Transl Med       Date:  2012-09-26       Impact factor: 17.956

Review 8.  Culture-based diagnostic microbiology in cystic fibrosis: can we simplify the complexity?

Authors:  Jane L Burns; Jean-Marc Rolain
Journal:  J Cyst Fibros       Date:  2013-10-03       Impact factor: 5.482

9.  Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum.

Authors:  Caroline G Baxter; Riina Rautemaa; Andrew M Jones; A Kevin Webb; Matthew Bull; Eshwar Mahenthiralingam; David W Denning
Journal:  Thorax       Date:  2013-03-19       Impact factor: 9.139

Review 10.  Emerging cystic fibrosis pathogens and the microbiome.

Authors:  Eshwar Mahenthiralingam
Journal:  Paediatr Respir Rev       Date:  2014-04-13       Impact factor: 2.726

View more
  36 in total

1.  Lung mapping seeks to crack microbial code in cystic fibrosis.

Authors:  Shraddha Chakradhar
Journal:  Nat Med       Date:  2015-08       Impact factor: 53.440

Review 2.  Integrating the microbiota of the respiratory tract with the unified airway model.

Authors:  Alissa S Hanshew; Marie E Jetté; Sarah P Rosen; Susan L Thibeault
Journal:  Respir Med       Date:  2017-03-22       Impact factor: 3.415

Review 3.  The Yin and Yang of Streptococcus Lung Infections in Cystic Fibrosis: a Model for Studying Polymicrobial Interactions.

Authors:  Jessie E Scott; George A O'Toole
Journal:  J Bacteriol       Date:  2019-05-08       Impact factor: 3.490

4.  Assessing Airway Microbiota in Cystic Fibrosis: What More Should Be Done?

Authors:  John J LiPuma
Journal:  J Clin Microbiol       Date:  2015-05-13       Impact factor: 5.948

5.  Pseudomonas aeruginosa Can Inhibit Growth of Streptococcal Species via Siderophore Production.

Authors:  Jessie E Scott; Kewei Li; Laura M Filkins; Bin Zhu; Sherry L Kuchma; Joseph D Schwartzman; George A O'Toole
Journal:  J Bacteriol       Date:  2019-03-26       Impact factor: 3.490

Review 6.  Cystic Fibrosis Airway Microbiome: Overturning the Old, Opening the Way for the New.

Authors:  George A O'Toole
Journal:  J Bacteriol       Date:  2018-01-24       Impact factor: 3.490

7.  Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens.

Authors:  Mona A Mahboubi; Lisa A Carmody; Bridget K Foster; Linda M Kalikin; Donald R VanDevanter; John J LiPuma
Journal:  J Clin Microbiol       Date:  2015-12-23       Impact factor: 5.948

8.  Availability of Zinc Impacts Interactions between Streptococcus sanguinis and Pseudomonas aeruginosa in Coculture.

Authors:  Kewei Li; Alex H Gifford; Thomas H Hampton; George A O'Toole
Journal:  J Bacteriol       Date:  2020-01-02       Impact factor: 3.490

Review 9.  Iron acquisition in the cystic fibrosis lung and potential for novel therapeutic strategies.

Authors:  Jean Tyrrell; Máire Callaghan
Journal:  Microbiology (Reading)       Date:  2015-12-04       Impact factor: 2.777

10.  "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Authors:  Peter H Gilligan; Damian G Downey; J Stuart Elborn; Patrick A Flume; Sebastian Funk; Deirdre Gilpin; Timothy J Kidd; John McCaughan; B Cherie Millar; Philip G Murphy; Jacqueline C Rendall; Michael M Tunney; John E Moore
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.